EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, IGM Biosciences's enterprise value is $-33.01 Mil.
IGM Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $2.68 Mil. Therefore, IGM Biosciences's EV-to-Revenue for today is -12.31.
The historical rank and industry rank for IGM Biosciences's EV-to-Revenue or its related term are showing as below:
IGMS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -54.2 Med: 137.3 Max: 1882.5
Current: -12.31
During the past 8 years, the highest EV-to-Revenue of IGM Biosciences was 1882.50. The lowest was -54.20. And the median was 137.30.
IGMS's EV-to-Revenue is ranked better than 97.39% of 995
companies
in the Biotechnology industry
Industry Median: 7.17
vs IGMS: -12.31
As of today (2025-05-25), IGM Biosciences's stock price is $1.25.
IGM Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.05. Therefore, IGM Biosciences's PS Ratio for today is 27.78.
IGM Biosciences EV-to-Revenue Historical Data
The historical data trend for IGM Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IGM Biosciences's EV-to-Revenue
For the Biotechnology subindustry, IGM Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGM Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGM Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where IGM Biosciences's EV-to-Revenue falls into.
IGM Biosciences's current Enterprise Value is $-33.01 Mil.
IGM Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGM Biosciences's share price for today is $1.25.
IGM Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGM Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of IGM Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGMS has been successfully added to your 